biostudies-literatureLinden MVetenskapsrådet•the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreementBarncancerfondenCancerfonden107https://www.ebi.ac.uk/biostudies/studies/S-EPMC12455829biostudies-literatureUnknown30(1)<h4>Background</h4>FET (FUS, EWSR1, and TAF15) fusion oncoproteins are characteristic for several sarcomas and leukemias, including myxoid liposarcoma and Ewing sarcoma. FET oncoproteins interact with the SWI/SNF chromatin remodeling complex subtypes cBAF, PBAF, and GBAF, but their impact on SWI/SNF compositions, interactions, and downstream epigenetic effects remains elusive.<h4>Methods</h4>We employ a comprehensive immunoprecipitation and quantitative mass spectrometry approach to determine the impact of FET oncoproteins on SWI/SNF composition and their interactomes. Validation of complex composition and interaction partners is performed by glycerol gradient sedimentation assays and co-immunofluorescence analysis. Furthermore, we determine the differential chromatin accessibility and genCellular & molecular biology lettersFET fusion oncoproteins enrich SWI/SNF complex subtypes and interaction partners.PMC1245582996506522-247010060092023-0223996631822-20802021-01008D2025-00032022-0030Andersson LAman PSjovall DJaako PLinden MJonasson ECrescitelli RFagman HStahlberg AAlbatrok HCanfjorden VGronqvist KfalseFET fusion oncoproteins enrich SWI/SNF complex subtypes and interaction partners.<h4>Background</h4>FET (FUS, EWSR1, and TAF15) fusion oncoproteins are characteristic for several sarcomas and leukemias, including myxoid liposarcoma and Ewing sarcoma. FET oncoproteins interact with the SWI/SNF chromatin remodeling complex subtypes cBAF, PBAF, and GBAF, but their impact on SWI/SNF compositions, interactions, and downstream epigenetic effects remains elusive.<h4>Methods</h4>We employ a comprehensive immunoprecipitation and quantitative mass spectrometry approach to determine the impact of FET oncoproteins on SWI/SNF composition and their interactomes. Validation of complex composition and interaction partners is performed by glycerol gradient sedimentation assays and co-immunofluorescence analysis. Furthermore, we determine the differential chromatin accessibility and gen2025-01-01T00:00:00Z2025 Sep2026-06-03T19:38:59.684Z2026-04-30T03:12:31.648ZS-EPMC124558294098802610.1186/s11658-025-00792-w